Tau, where are we now?

Journal of Alzheimer's Disease

Volumn 4, Issue 5, 2002, Pages 375-398

  Johnson, Gail V W ^a   Bailey, Craig D C ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAU PROTEIN;

ALZHEIMER DISEASE; CHROMOSOME 17; DEGENERATIVE DISEASE; FRONTOTEMPORAL DEMENTIA; GENE FUNCTION; GENE MUTATION; HUMAN; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW;

EID: 0036813736     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2002-4505     Document Type: Review

References (239)

1. The Lund and Manchester Groups, Clinical and neuropathological criteria for frontotemporal dementia, J Neurol Neurosurg Psychiatry 57 (1994), 416-418.
2. A. Abraha, N. Ghoshal, T.C. Gamblin, V. Cryns, R.W. Berry, J. Kuret and L.I. Binder, C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease, J Cell Sci 113 (2000), 3737-3745.
3. A. Alonso, T. Zaidi, M. Novak, I. Grundke-Iqbal and K. Iqbal, Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments, Proc Natl Acad Sci USA 98 (2001), 6923-6928.
4. A.C. Alonso, I. Grundke-Iqbal and K. Iqbal, Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules, Nat Med 2 (1996), 783-787.
5. T. Arai, K. Ikeda, H. Akiyama, Y. Shikamoto, K. Tsuchiya, S. Yagishita, T. Beach, J. Rogers, C. Schwab and P.L. McGeer, Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy, Acta Neuropathol (Berl) 101 (2001), 167-173.
6. C.S. Arnold, G.V. Johnson, R.N. Cole, D.L. Dong, M. Lee and G.W. Hart, The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine, J Biol Chem 271 (1996), 28741-28744.
7. C. Atzori, B. Ghetti, R. Piva, A.N. Srinivasan, P. Zolo, M.B. Delisle, S.S. Mirra and A. Migheli, Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis, J Neuropathol Exp Neurol 60 (2001), 1190-1197.
8. M. Baker, D. Graff-Radford, F. Wavrant De Vrieze, N. Graff-Radford, R.C. Petersen, E. Kokmen, B. Boeve, L. Myllykangas, T. Polvikoski, R. Sulkava, A. Verkoniemmi, P. Tienari, M. Haltia, J. Hardy, M. Hutton and J. Perez-Tur, No association between TAU haplotype and Alzheimer's disease in population or clinic based series or in familial disease, Neurosci Lett 285 (2000), 147-149.
9. M. Baker, I. Litvan, H. Houlden, J. Adamson, D. Dickson, J. Perez-Tur, J. Hardy, T. Lynch, E. Bigio and M. Hutton, Association of an extended haplotype in the tau gene with progressive supranuclear palsy, Hum Mol Genet 8 (1999), 711-715.
10. P. Bennett, V. Bonifati, U. Bonuccelli, C. Colosimo, M. De Mari, G. Fabbrini, R. Marconi, G. Meco, D.J. Nicholl, F. Stocchi, N. Vanacore, P. Vieregge and A.C. Williams, Direct genetic evidence for involvement of tau in progressive supranuclear palsy. European Study Group on Atypical Parkinsonism Consortium, Neurology 51 (1998), 982-985.
11. R. Borghi, L. Giliberto, A. Assini, A. Delacourte, G. Perry, M.A. Smith, P. Strocchi, D. Zaccheo and M. Tabaton, Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy, Neurology 58 (2002), 589-592.
12. A. Boutajangout, K. Leroy, N. Touchet, M. Authelet, V. Blanchard, G. Tremp, L. Pradier and J.P. Brion, Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1, Neurosci Lett 318 (2002), 29-33.
13. R. Brandt, J. Leger and G. Lee, Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain, J Cell Biol 131 (1995), 1327-1340.
14. J.P. Brion, G. Tremp and J.N. Octave, Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease, Am J Pathol 154 (1999), 255-270.
15. L. Buee and A. Delacourte, Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease, Brain Pathol 9 (1999), 681-693.
16. O. Bugiani, FTDP-17: Phenotypical heterogeneity within P301S, Ann Neurol 48 (2000), 126.
17. O. Bugiani, J.R. Murrell, G. Giaccone, M. Hasegawa, G. Ghigo, M. Tabaton, M. Morbin, A. Primavera, F. Carella, C. Solaro, M. Grisoli, M. Savoiardo, M.G. Spillantini, F. Tagliavini, M. Goedert and B. Ghetti, Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau, J Neuropathol Exp Neurol 58 (1999), 667-677.
18. D.A. Butterfield, J. Drake, C. Pocernich and A. Castegna, Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid beta-peptide, Trends Mol Med 7 (2001), 548-554.
19. A. Caceres and K.S. Kosik, Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons, Nature 343 (1990), 461-463.
20. A. Caceres, S. Potrebic and K.S. Kosik, The effect of tau antisense oligonucleotides on neurite formation of cultured cerebellar macroneurons, J Neurosci 11 (1991), 1515-1523.
21. N. Canu, L. Dus, C. Barbato, M.T. Ciotti, C. Brancolini, A.M. Rinaldi, M. Novak, A. Cattaneo, A. Bradbury and P. Calissano, Tau cleavage and dephosphorylation in cerebellar granule neurons undergoing apoptosis, J Neurosci 18 (1998), 7061-7074.
22. D. Caparros-Lefebvre, N. Sergeant, A. Lees, A. Camuzat, S. Daniel, A. Lannuzel, A. Brice, E. Tolosa, A. Delacourte and C. Duyckaerts, Guadeloupean parkinsonism: A cluster of progressive supranuclear palsy-like tauopathy, Brain 125 (2002), 801-811.
23. G. Carmel, E.M. Mager, L.I. Binder and J. Kuret, The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology, J Biol Chem 271 (1996), 32789-32795.
24. C.B. Chambers, J.M. Lee, J.C. Troncoso, S. Reich and N.A. Muma, Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease, Ann Neurol 46 (1999), 325-332.
25. L.N. Clark, P. Poorkaj, Z. Wszolek, D.H. Geschwind, Z.S. Nasreddine, B. Miller, D. Li, H. Payami, F. Awert, K. Markopoulou, A. Andreadis, I. D'Souza, V.M. Lee, L. Reed, J.Q. Trojanowski, V. Zhukareva, T. Bird, G. Schellenberg and K.C. Wilhelmsen, Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17, Proc Natl Acad Sci USA 95 (1998), 13103-13107.
26. C. Conrad, A. Andreadis, J.Q. Trojanowski, D.W. Dickson, D. Kang, X. Chen, W. Wiederholt, L. Hansen, E. Masliah, L.J. Thal, R. Katzman, Y. Xia and T. Saitoh, Genetic evidence for the involvement of tau in progressive supranuclear palsy, Ann Neurol 41 (1997), 277-281.
27. N.J. Cordato, C. Pantelis, G.M. Halliday, D. Velakoulis, S.J. Wood, G.W. Stuart, J. Currie, M. Soo, G. Olivieri, G.A. Broe and J.G. Morris, Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy, Brain 125 (2002), 789-800.
28. D.A. Cross, D.R. Alessi, P. Cohen, M. Andjelkovich and B.A. Hemmings, Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B, Nature 378 (1995), 785-789.
29. R.A. Crowther and M. Goedert, Abnormal tau-containing filaments in neurodegenerative diseases, J Struct Biol 130 (2000), 271-279.
30. R. Dajani, E. Fraser, S.M. Roe, N. Young, V. Good, T.C. Dale and L.H. Pearl, Crystal structure of glycogen synthase kinase 3beta. structural basis for phosphate-primed substrate specificity and autoinhibition, Cell 105 (2001), 721-732.
31. T.C. Dale, Signal transduction by the Wnt family of ligands, Biochem J 329 (1998), 209-223.
32. G. D'Arcangelo, R. Homayouni, L. Keshvara, D.S. Rice, M. Sheldon and T. Curran, Reelin is a ligand for lipoprotein receptors, Neuron 24 (1999), 471-479.
33. P.K. Davis and G.V. Johnson, The microtubule binding of Tau and high molecular weight Tau in apoptotic PC12 cells is impaired because of altered phosphorylation, J Biol Chem 274 (1999), 35686-35692.
34. P.K. Davis and G.V. Johnson, The microtubule binding of tau and high molecular weight tau in apoptotic PC12 cells is impaired because of altered phosphorylation, J Biol Chem 274 (1999), 35686-35692.
35. H.N. Dawson, A. Ferreira, M.V. Eyster, N. Ghoshal, L.I. Binder and M.P. Vitek, Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice, J Cell Sci 114 (2001), 1179-1187.
36. R. Dayanandan, M. Van Slegtenhorst, T.G. Mack, L. Ko, S.H. Yen, K. Leroy, J.P. Brion, B.H. Anderton, M. Hutton and S. Lovestone, Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation, FEBS Lett 446 (1999), 228-232.
37. P. Delobel, S. Flament, M. Hamdane, R. Jakes, A. Rousseau, A. Delacourte, J.P. Vilain, M. Goedert and L. Buee, Functional characterization of FTDP-17 tau gene mutations through their effects on Xenopus oocyte maturation, J Biol Chem 277 (2002), 9199-9205.
38. E. Di Maria, M. Tabaton, T. Vigo, G. Abbruzzese, E. Bellone, C. Donati, E. Frasson, R. Marchese, P. Montagna, D.G. Munoz, P.P. Pramstaller, G. Zanusso, F. Ajmar and P. Mandich, Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy, Ann Neurol 47 (2000), 374-377.
39. I. D'Souza, P. Poorkaj, M. Hong, D. Nochlin, V.M. Lee, T.D. Bird and G.D. Schellenberg, Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements, Proc Natl Acad Sci USA 96 (1999), 5598-5603.
40. I. D'Souza and G.D. Schellenberg, Determinants of 4-repeat tau expression. Coordination between enhancing and inhibitory splicing sequences for exon 10 inclusion, J Biol Chem 275 (2000), 17700-17709.
41. K. Duff, H. Knight, L.M. Refolo, S. Sanders, X. Yu, M. Picciano, B. Malester, M. Hutton, J. Adamson, M. Goedert, K. Burki and P. Davies, Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes, Neurobiol Dis 7 (2000), 87-98.
42. C. Dumanchin, A. Camuzat, D. Campion, P. Verpillat, D. Hannequin, B. Dubois, P. Saugier-Veber, C. Martin, C. Penet, F. Charbonnier, Y. Agid, T. Frebourg and A. Brice, Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism, Hum Mol Genet 7 (1998), 1825-1829.
43. A. Ebneth, R. Godemann, K. Stamer, S. Illenberger, B. Trinczek and E. Mandelkow, Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: Implications for Alzheimer's disease, J Cell Biol 143 (1998), 777-794.
44. F.J. Ekinci and T.B. Shea, Phosphorylation of tau alters its association with the plasma membrane, Cell Mol Neurobiol 20 (2000), 497-508.
45. R.J. Ellis, Macromolecular crowding: Obvious but underappreciated, Trends Biochem Sci 26 (2001), 597-604.
46. W. Elyaman, F. Terro, N.S. Wong and J. Hugon, In vivo activation and nuclear translocation of phosphorylated glycogen synthase kinase-3beta in neuronal apoptosis: Links to tau phosphorylation, Eur J Neurosci 15 (2002), 651-660.
47. Q.W. Fan, W. Yu, T. Senda, K. Yanagisawa and M. Michikawa, Cholesterol-dependent modulation of tau phosphorylation in cultured neurons, J Neurochem 76 (2001), 391-400.
48. L. Fasulo, G. Ugolini, M. Visintin, A. Bradbury, C. Brancolini, V. Verzillo, M. Novak and A. Cattaneo, The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis, J Neurochem 75 (2000), 624-633.
49. A. Ferreira, Q. Lu, L. Orecchio and K.S. Kosik, Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta, Mol Cell Neurosci 9 (1997), 220-234.
50. I. Ferrer, R. Blanco, M. Carmona, R. Ribera, E. Goutan, B. Puig, M.J. Rey, A. Cardozo, F. Vinals and T Ribalta, Phosphorylated map kinase (ERK1, ERK2), expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration, Brain Pathol 11 (2001), 144-158.
51. S. Frame, P. Cohen and R.M. Biondi, A common phosphate binding site explains the unique substrate specificity of gsk3 and its inactivation by phosphorylation, Mol Cell 7 (2001), 1321-1327.
52. P. Friedhoff, A. Schneider, E.M. Mandelkow and E. Mandelkow, Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution, Biochemistry 37 (1998), 10223-10230.
53. P. Friedhoff, M. von Bergen, E.M. Mandelkow, P. Davies and E. Mandelkow, A nucleated assembly mechanism of Alzheimer paired helical filaments, Proc Natl Acad Sci USA 95 (1998), 15712-15717.
54. P. Friedhoff, M. von Bergen, E.M. Mandelkow and E. Mandelkow, Structure of tau protein and assembly into paired helical filaments, Biochim Biophys Acta 1502 (2000), 122-132.
55. S. Fukumoto, C.M. Hsieh, K. Maemura, M.D. Layne, S.F. Yet, K.H. Lee, T. Matsui, A. Rosenzweig, W.G. Taylor, J.S. Rubin, M.A. Perrella and M.E. Lee, Akt participation in the Wnt signaling pathway through Dishevelled, J Biol Chem 276 (2001), 17479-17483.
56. K. Furukawa, I. D'Souza, C.H. Crudder, H. Onodera, Y. Itoyama, P. Poorkaj, T.D. Bird and G.D. Schellenberg, Pro-apoptotic effects of tau mutations in chromosome 17 frontotemporal dementia and parkinsonism, Neuroreport 11 (2000), 57-60.
57. T.C. Gamblin, M.E. King, H. Dawson, M.P. Vitek, J. Kuret, R.W. Berry and L.I. Binder, In vitro polymerization of tau protein monitored by laser light scattering: Method and application to the study of FTDP-17 mutants, Biochemistry 39 (2000), 6136-6144.
58. R. Gantier, D. Gilbert, C. Dumanchin, D. Campion, D. Davoust, F. Toma and T. Frebourg, The pathogenic L392V mutation of presenilin 1 decreases the affinity to glycogen synthase kinase-3 beta, Neurosci Lett 283 (2000), 217-220.
59. N. Ghoshal, J.F. Smiley, A.J. DeMaggio, M.F. Hoekstra, E.J. Cochran, L.I. Binder and J. Kuret, A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease, Am J Pathol 155 (1999), 1163-1172.
60. G.E. Gibson and H.M. Huang, Oxidative processes in the brain and non-neuronal tissues as biomarkers of Alzheimer's disease, Front Biosci 7 (2002), D1007-1015.
61. M. Goedert, Neurofibrillary pathology of Alzheimer's disease and other tauopathies, Prog Brain Res 117 (1998), 287-306.
62. M. Goedert, R. Jakes and R.A. Crowther, Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments, FEBS Lett 450 (1999), 306-311.
63. M. Goedert, S. Satumtira, R. Jakes, M.J. Smith, C. Kamibayashi, C.L. White III and E. Sontag, Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations, J Neurochem 75 (2000), 2155-2162.
64. M. Gorath, T. Stahnke, T. Mronga, O. Goldbaum and C. Richter-Landsberg, Developmental changes of tau protein and mRNA in cultured rat brain oligodendrocytes, Glia 36 (2001), 89-101.
65. J. Gotz, R. Barmettler, A. Ferrari, M. Goedert, A. Probst and R.M. Nitsch, In vivo analysis of wild-type and FTDP-17 tau transgenic mice, Ann N YAcad Sci 920 (2000), 126-133.
66. J. Gotz, F. Chen, R. Barmettler and R.M. Nitsch, Tau filament formation in transgenic mice expressing P301L tau, J Biol Chem 276 (2001), 529-534.
67. J. Gotz, F. Chen, J. van Dorpe and R.M. Nitsch, Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils, Science 293 (2001), 1491-1495.
68. J. Gotz and R.M. Nitsch, Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice, Neuroreport 12 (2001), 2007-2016.
69. J. Gotz, M. Tolnay, R. Barmettler, F. Chen, A. Probst and R.M. Nitsch, Oligodendroglial tau filament formation in transgenic mice expressing G272V tau, Eur J Neurosci 13 (2001), 2131-2140.
70. C.A. Grimes and R.S. Jope, The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling, Prog Neurobiol 65 (2001), 391-426.
71. S.D. Gross and R.A. Anderson, Casein kinase I: Spatial organization and positioning of a multifunctional protein kinase family, Cell Signal 10 (1998), 699-711.
72. A. Grover, M. DeTure, S.H. Yen and M. Hutton, Effects on splicing and protein function of three mutations in codon N296 of tau in vitro, Neurosci Lett 323 (2002), 33-36.
73. A. Grover, H. Houlden, M. Baker, J. Adamson, J. Lewis, G. Prihar, S. Pickering-Brown, K. Duff and M. Hutton, 5′ Splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10, J Biol Chem 274 (1999), 15134-15143.
74. N. Gustke, B. Trinczek, J. Biernat, E.M. Mandelkow and E. Mandelkow, Domains of tau protein and interactions with microtubules, Biochemistry 33 (1994), 9511-9522.
75. G.F. Hall, B. Chu, G. Lee and J. Yao, Human tau filaments induce microtubule and synapse loss in an in vivo model of neurofibrillary degenerative disease, J Cell Sci 113 (2000), 1373-1387.
76. G.F. Hall, V.M. Lee, G. Lee and J. Yao, Staging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathy, Am J Pathol 158 (2001), 235-246.
77. A. Harada, K. Oguchi, S. Okabe, J. Kuno, S. Terada, T. Ohshima, R. Sato-Yoshitake, Y. Takei, T Noda and N. Hirokawa, Altered microtubule organization in small-calibre axons of mice lacking tau protein, Nature 369 (1994), 488-491.
78. J.A. Hartigan and G.V. Johnson, Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway, J Biol Chem 274 (1999), 21395-21401.
79. J.A. Hartigan, W.C. Xiong and G.V. Johnson, Glycogen synthase kinase 3beta is tyrosine phosphorylated by pyk2, Biochem Biophys Res Commun 284 (2001), 485-489.
80. M. Hashiguchi, K. Sobue and H.K. Paudel, 14-3-3zeta is an effector of tau protein phosphorylation, J Biol Chem 275 (2000), 25247-25254.
81. J.J. Hauw, S.E. Daniel, D. Dickson, D.S. Horoupian, K. Jellinger, P.L. Lantos, A. McKee, M. Tabaton and I. Litvan, Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy), Neurology 44 (1994), 2015-2019.
82. S. Hayashi, Y. Toyoshima, M. Hasegawa, Y. Umeda, K. Wakabayashi, S. Tokiguchi, T. Iwatsubo and H. Takahashi, Late-onset frontotemporal dementia with a novel exon 1 (Arg5His), tau gene mutation, Ann Neurol 51 (2002), 525-530.
83. P. Heutink, Untangling tau-related dementia, Hum Mol Genet 9 (2000), 979-986.
84. L. Hicke, Protein regulation by monoubiquitin, Nat Rev Mol Cell Biol 2 (2001), 195-201.
85. T. Hiesberger, M. Trommsdorff, B.W. Howell, A. Goffinet, M.C. Mumby, J.A. Cooper and J. Herz, Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation, Neuron 24 (1999), 481-489.
86. J.J. Higgins, I. Litvan, L.T. Pho, W. Li and L.E. Nee, Progressive supranuclear gaze palsy is in linkage disequilibrium with the tau and not the alpha-synuclein gene, Neurology 50 (1998), 270-273.
87. L. Ho, Z. Xiang, P. Mukherjee, W. Zhang, N. De Jesus, M. Mirjany, S. Yemul and G.M. Pasinetti, Gene expression profiling of the tau mutant (P301L) transgenic mouse brain, Neurosci Lett 310 (2001), 1-4.
88. M. Hong and V.M. Lee, Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons, J Biol Chem 272 (1997), 19547-19553.
89. M. Hong, V. Zhukareva, V. Vogelsberg-Ragaglia, Z. Wszolek, L. Reed, B.I. Miller, D.H. Geschwind, T.D. Bird, D. McKeel, A. Goate, J.C. Morris, K.C. Wilhelmsen, G.D. Schellenberg, J.Q. Trojanowski and V.M. Lee, Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17, Science 282 (1998), 1914-1917.
90. H. Houlden et al., Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype, Neurology 56 (2001), 1702-1706.
91. K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. Yang and G. Cole, Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice, Science 274 (1996), 99-102.
92. K. Hughes, E. Nikolakaki, S.E. Plyte, N.F. Totty and J.R. Woodgett, Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation, EMBO J 12 (1993), 803-808.
93. M. Hutton, Missense and splice site mutations in tau associated with FTDP-17: Multiple pathogenic mechanisms, Neurology 56 (2001), S21-25.
94. M. Hutton et al., Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17, Nature 393 (1998), 702-705.
95. S. Ikeda, S. Kishida, H. Yamamoto, H. Murai, S. Koyama and A. Kikuchi, Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and betacatenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin, EMBO J 17 (1998), 1371-1384.
96. S. Ikegami, A. Harada and N. Hirokawa, Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice, Neurosci Lett 279 (2000), 129-132.
97. T. Ishihara, M. Hong, B. Zhang, Y. Nakagawa, M.K. Lee, J.Q. Trojanowski and V.M. Lee, Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform, Neuron 24 (1999), 751-762.
98. T. Ishihara, B. Zhang, M. Higuchi, Y. Yoshiyama, J.Q. Trojanowski and V.M. Lee, Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice, Am J Pathol 158 (2001), 555-562.
99. T. Iwatsubo, M. Hasegawa and Y. Ihara, Neuronal and glial tau-positive inclusions in diverse neurologic diseases share common phosphorylation characteristics, Acta Neuropathol 88 (1994), 129-136.
100. G.R. Jackson, M. Wiedau-Pazos, T.K. Sang, N. Wagle, C.A. Brown, S. Massachi and D.H. Geschwind, Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila, Neuron 34 (2002), 509-519.
101. G.A. Jicha, R. Bowser, I.G. Kazam and P. Davies, Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau, J Neurosci Res 48 (1997), 128-132.
102. G.V.W. Johnson and J.A. Hartigan, Tau protein in normal and Alzheimer's Disease brain: An update, J Alz Dis 1 (1999), 329-351.
103. G.V.W. Johnson and S.M. Jenkins, Tau protein in normal and Alzheimer's disease brain, J Alz Dis 1 (1999), 307-328.
104. T. Kampers, M. Pangalos, H. Geerts, H. Wiech and E. Mandelkow, Assembly of paired helical filaments from mouse tau: Implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer's disease, FEBS Lett 451 (1999), 39-44.
105. M.E. King, V. Ahuja, L.I. Binder and J. Kuret, Ligand-dependent tau filament formation: Implications for Alzheimer's disease progression, Biochemistry 38 (1999), 14851-14859.
106. M.E. King, T.C. Gamblin, J. Kuret and L.I. Binder, Differential assembly of human tau isoforms in the presence of arachidonic acid, J Neurochem 74 (2000), 1749-1757.
107. M.E. King, N. Ghoshal, J.S. Wall, L.I. Binder and H. Ksiezak-Reding, Structural analysis of Pick's disease-derived and in vitro-assembled tau filaments, Am J Pathol 158 (2001), 1481-1490.
108. S. Kins, A. Crameri, D.R. Evans, B.A. Hemmings, R.M. Nitsch and J. Gotz, Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice, J Biol Chem 276 (2001), 38193-38200.
109. C. Klein, E.M. Kramer, A.M. Cardine, B. Schraven, R. Brandt and J. Trotter, Process outgrowth of oligodendrocytes is promoted by interaction of fyn kinase with the cytoskeletal protein tau, J Neurosci 22 (2002), 698-707.
110. J. Knops, K.S. Kosik, G. Lee, J.D. Pardee, L. Cohen-Gould and L. McConlogue, Overexpression of tau in a nonneuronal cell induces long cellular processes, J Cell Biol 114 (1991), 725-733.
111. T. Komori, Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease, Brain Pathol 9 (1999), 663-679.
112. P.K. Krishnamurthy, J.L. Mays, G.N. Bijur and G.V. Johnson, Transient oxidative stress in SH-SY5Y human neuroblastoma cells results in caspase dependent and independent cell death and tau proteolysis, J Neurosci Res 61 (2000), 515-523.
113. H. Ksiezak-Reding, D. He, W. Gordon-Krajcer, Y. Kress, S. Lee and D.W. Dickson, Induction of Alzheimer-specific Tau epitope AT100 in apoptotic human fetal astrocytes, Cell Motil Cytoskeleton 47 (2000), 236-252.
114. J. Kuret, G.S. Johnson, D. Cha, E.R. Christenson, A.J. DeMaggio and M.F. Hoekstra, Casein kinase 1 is tightly associated with paired-helical filaments isolated from Alzheimer's disease brain, J Neurochem 69 (1997), 2506-2515.
115. G. Lee, L.H. Do and J.M. Litersky, Tyrosine phosphorylation of tau, Soc Neurosci Abstr 542.1 (2001).
116. G. Lee, S.T. Newman, D.L. Gard and H. Band, Panchamoorthy G, Tau interacts with src-family non-receptor tyrosine kiniases, J Cell Sci 111 (1998), 3167-3177.
117. J.S. Lee, A. Ishimoto and S. Yanagawa, Characterization of mouse dishevelled (Dvl) proteins in Wnt/Wingless signaling pathway, J Biol Chem 274 (1999), 21464-21470.
118. V.M. Lee, M. Goedert and J.Q. Trojanowski, Neurodegenerative tauopathies, Annu Rev Neurosci 24 (2001), 1121-1159.
119. V.M.Y. Lee, Tauist and baptists united - Well almost! Science 293 (2001), 1446-1447.
120. K. Leroy, A. Boutajangout, M. Authelet, J.R. Woodgett, B.H. Anderton and J.P. Brion, The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease, Acta Neuropathol (Berl) 103 (2002), 91-99.
121. M. Lesort and G.V. Johnson, Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons, Neuroscience 99 (2000), 305-316.
122. M. Lesort, R.S. Jope and G.V.W. Johnson, Insulin transiently increases tau phosphorylation: Involvement of glycogen synthase kinase-3b and fyn tyrosine kinase, J Neurochem 72 (1999), 576-584.
123. S. Lev, H. Moreno, R. Martinez, P. Canoll, E. Peles, J.M. Musacchio, G.D. Plowman, B. Rudy and J. Schlessinger, Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions, Nature 376 (1995), 737-745.
124. J. Lewis, D.W. Dickson, W.L. Lin, L. Chisholm, A. Corral, G. Jones, S.H. Yen, N. Sahara, L. Skipper, D. Yager, C. Eckman, J. Hardy, M. Hutton and E. McGowan, Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP, Science 293 (2001), 1487-1491.
125. J. Lewis, E. McGowan, J. Rockwood, H. Melrose, P. Nacharaju, M. Van Slegtenhorst, K. Gwinn-Hardy, M. Paul Murphy, M. Baker, X. Yu, K. Duff, J. Hardy, A. Corral, W.L. Lin, S.H. Yen, D.W. Dickson, P. Davies and M. Hutton, Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein, Nat Genet 25 (2000), 402-405.
126. L. Li, H. Yuan, C.D. Weaver, J. Mao, G.H. Farr III, D.J. Sussman, J. Jonkers, D. Kimelman and D. Wu, Axin and Frat1 interact with dv1 and GSK, bridging Dv1 to GSK in Wnt-mediated regulation of LEF-1, EMBO J 18 (1999), 4233-4240.
127. H. Liao, Y. Li, D.L. Brautigan and G.G. Gundersen, Protein phosphatase 1 is targeted to microtubules by the microtubule-associated protein Tau, J Biol Chem 273 (1998), 21901-21908.
128. F. Lim, F. Hernandez, J.J. Lucas, P. Gomez-Ramos, M.A. Moran and J. Avila, FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain, Mol Cell Neurosci 18 (2001), 702-714.
129. L. Liscum, Niemann-Pick type C mutations cause lipid traffic jam, Traffic 1 (2000), 218-225.
130. I. Litvan, Y. Agid, D. Calne, G. Campbell, B. Dubois, R.C. Duvoisin, C.G. Goetz, L.I. Golbe, J. Grafman, J.H. Growdon, M. Hallett, J. Jankovic, N.P. Quinn, E. Tolosa and D.S. Zee, Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop, Neurology 47 (1996), 1-9.
131. I. Litvan, J.J. Hauw, J.J. Bartko, P.L. Lantos, S.E. Daniel, D.S. Horoupian, A. McKee, D. Dickson, C. Bancher, M. Tabaton, K. Jellinger and D.W. Anderson, Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders, J Neuropathol Exp Neurol 55 (1996), 97-105.
132. C. Liu, Y. Li, M. Semenov, C. Han, G.H. Baeg, Y. Tan, Z. Zhang, X. Lin and X. He, Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism, Cell 108 (2002), 837-847.
133. C.W. Liu, G. Lee and D.G. Jay, Tau is required for neurite outgrowth and growth cone motility of chick sensory neurons, Cell Motil Cytoskeleton 43 (1999), 232-242.
134. W.K. Liu, TV. Le, J. Adamson, M. Baker, N. Cookson, J. Hardy, M. Hutton, S.H. Yen and D.W. Dickson, Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy, Ann Neurol 50 (2001), 494-502.
135. S.K. Loftus, J.A. Morris, E.D. Carstea, J.Z. Gu, C. Cummings, A. Brown, J. Ellison, K. Ohno, M.A. Rosenfeld, D.A. Tagle, P.G. Pentchev and W.J. Pavan, Murine model of Niemann-Pick C disease: Mutation in a cholesterol homeostasis gene, Science 277 (1997), 232-235.
136. S. Lovestone, C.H. Reynolds, D. Latimer, D.R. Davis, B.H. Anderton, J.M. Gallo, D. Hanger, S. Mulot, B. Marquardt and S. Stabel et al., Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells, Curr Biol 4 (1994), 1077-1086.
137. M. Lu and K.S. Kosik, Competition for microtubule-binding with dual expression of tau missense and splice isoforms, Mol Biol Cell 12 (2001), 171-184.
138. P.J. Lu, G. Wulf, X.Z. Zhou, P. Davies and K.P. Lu, The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein, Nature 399 (1999), 784-788.
139. T. Maas, J. Eidenmuller and R. Brandt, Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments, J Biol Chem 275 (2000), 15733-15740.
140. T.G. Mack, R. Dayanandan, M. Van Slegtenhorst, A. Whone, M. Hutton, S. Lovestone and B.H. Anderton, Tau proteins with frontotemporal dementia-17 mutations have both altered expression levels and phosphorylation profiles in differentiated neuroblastoma cells, Neuroscience 108 (2001), 701-712.
141. C. Mailliot, N. Sergeant, T. Bussiere, M.L. Caillet-Boudin, A. Delacourte and L. Buee, Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes, FEBS Lett 433 (1998), 201-204.
142. N. Matsumura, T. Yamazaki and Y. Ihara, Stable expression in Chinese hamster ovary cells of mutated tau genes causing frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), Am J Pathol 154 (1999), 1649-1656.
143. M.P. Mattson, Apoptosis in neurodegenerative disorders, Nat Rev Mol Cell Biol 1 (2000), 120-129.
144. J.C. Mills, V.M. Lee and R.N. Pittman, Activation of a PP2A-like phosphatase and dephosphorylation of tau protein characterize onset of the execution phase of apoptosis, J Cell Sci 111 (1998), 625-636.
145. A.P. Minton, The influence of macromolecular crowding and macromolecular confinement on biochemical reactions in physiological media, J Biol Chem 276 (2001), 10577-10580.
146. S.S. Mirra, J.R. Murrell, M. Gearing, M.G. Spillantini, M. Goedert, R.A. Crowther, A.I. Levey, R. Jones, J. Green, J.M. Shoffner, B.H. Wainer, M.L. Schmidt, J.Q. Trojanowski and B. Ghetti, Tau pathology in a family with dementia and a P301L mutation in tau, J Neuropathol Exp Neurol 58 (1999), 335-345.
147. K. Miyamoto, A. Kowalska, M. Hasegawa, T. Tabira, K. Takahashi, W. Araki, I. Akiguchi and A. Ikemoto, Familial frontotemporal dementia and parkinsonism with a novel mutation at an intron 10+11-splice site in the tau gene, Ann Neurol 50 (2001), 117-120.
148. P. Mookherjee and G.V. Johnson, Tau phosphorylation during apoptosis of human SH-SY5Y neuroblastoma cells, Brain Res 921 (2001), 31-43.
149. H. Mori, M. Nishimura, Y. Namba and M. Oda, Corticobasal degeneration: A disease with widespread appearance of abnormal tau and neurofibrillary tangles, and its relation to progressive supranuclear palsy, Acta Neuropathol 88 (1994), 113-121.
150. M. Morishima-Kawashima, M. Hasegawa, K. Takio, M. Suzuki, K. Titani and Y. Ihara, Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments, Neuron 10 (1993), 1151-1160.
151. H.R. Morris, J.C. Janssen, O. Bandmann, S.E. Daniel, M.N. Rossor, A.J. Lees and N.W. Wood, The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases, J Neurol Neurosurg Psychiatry 66 (1999), 665-667.
152. A. Mudher et al., Dishevelled Regulates the Metabolism of Amyloid Precursor Protein via Protein Kinase C/Mitogen-Activated Protein Kinase and c-Jun Terminal Kinase, J Neurosci 21 (2001), 4987-4995.
153. J.R. Murrell, M.G. Spillantini, P. Zolo, M. Guazzelli, M.J. Smith, M. Hasegawa, F. Redi, R.A. Crowther, P. Pietrini, B. Ghetti and M. Goedert, Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits, J Neuropathol Exp Neurol 58 (1999), 1207-1226.
154. S.N. Murthy, J.H. Wilson, T.J. Lukas, K. Kuret and L. Lorand, Cross-linking sites of the human tau protein, probed by reactions with human transglutaminase, J Neurochem 71 (1998), 2607-2614.
155. P. Nacharaju, J. Lewis, C. Easson, S. Yen, J. Hackett, M. Hutton and S.H. Yen, Accelerated filament formation from tau protein with specific
156. Z.S. Nasreddine, M. Loginov, L.N. Clark, J. Lamarche, B.L. Miller, A. Lamontagne, V. Zhukareva, V.M. Lee, K.C. Wilhelmsen and D.H. Geschwind, From genotype to phenotype: A clinical pathological, and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17), caused by the P301L tau mutation, Ann Neurol 45 (1999), 704-715.
157. P. Navas, N. Muma, Y. Jin, K. Shannon, E. Cochran, J.Q. Trojanowski, V.M. Lee and G.D. Schellenberg, Pathological and biochemical characterization of a tau R5L mutation in a single case of PSP, Soc Neurosci Abstr 429.4 (2001).
158. D. Neary and J. Snowden, Fronto-temporal dementia: Nosology, neuropsychology, and neuropathology, Brain Cogn 31 (1996), 176-187.
159. M. Neumann, W. Schulz-Schaeffer, R.A. Crowther, M.J. Smith, M.G. Spillantini, M. Goedert and H.A. Kretzschmar, Pick's disease associated with the novel Tau gene mutation K369I, Ann Neurol 50 (2001), 503-513.
160. M. Neystat, M. Rzhetskaya, T.F. Oo, N. Kholodilov, O. Yarygina, A. Wilson, B.F. El-Khodor and R.E. Burke, Expression of cyclin-dependent kinase 5 and its activator p35 in models of induced apoptotic death in neurons of the substantia nigra in vivo, J Neurochem 77 (2001), 1611-1625.
161. R. Nuydens, G. Van Den Kieboom, C. Nolten, C. Verhulst, P. Van Osta, K. Spittaels, C. Van den Haute, E. De Feyter, H. Geerts and F. Van Leuven, Coexpression of GSK-3beta corrects phenotypic aberrations of dorsal root ganglion cells, cultured from adult transgenic mice overexpressing human protein tau, Neurobiol Dis 9 (2002), 38-48.
162. K. Okamoto, S. Hirai, T. Iizuka, T. Yanagisawa and M. Watanabe, Reexamination of granulovacuolar degeneration, Acta Neuropathol 82 (1991), 340-345.
163. R. Oliva, E. Tolosa, M. Ezquerra, J.L. Molinuevo, F. Valldeoriola, J. Burguera, M. Calopa, M. Villa and F. Ballesta, Significant changes in the tau A0 and A3 alleles in progressive supranuclear palsy and improved genotyping by silver detection, Arch Neurol 55 (1998), 1122-1124.
164. P. Pastor, E. Pastor, C. Carnero, R. Vela, T. Garcia, G. Amer, E. Tolosa and R. Oliva, Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene, Ann Neurol 49 (2001), 263-267.
165. G.N. Patrick, L. Zukerberg, M. Nikolic, S. de la Monte, R Dikkes and L.H. Tsai, Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration, Nature 402 (1999), 615-622.
166. M. Perez, M. Arrasate, E. Montejo De Garcini, V. Munoz and J. Avila, In vitro assembly of tau protein: Mapping the regions involved in filament formation, Biochemistry 40 (2001), 5983-5991.
167. M. Perez, F. Lim, M. Arrasate and J. Avila, The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules, J Neurochem 74 (2000), 2583-2589.
168. G. Perry, M. Kawai, M. Tabaton, M. Onorato, P. Mulvihill, P. Richey, A. Morandi, J.A. Connolly and P. Gambetti, Neuropil threads of Alzheimer's disease show a marked alteration of the normal cytoskeleton, J Neurosci 11 (1991), 1748-1755.
169. G. Pigino, A. Pelsman, H. Mori and J. Busciglio, Presenilin-1 mutations reduce cytoskeletal association, deregulate neurite growth, and potentiate neuronal dystrophy and tau phosphorylation, J Neurosci 21 (2001), 834-842.
170. P. Polakis, Wnt signaling and cancer, Genes Dev 14 (2000), 1837-1851.
171. P. Poorkaj,T.D. Bird, E. Wijsman, E. Nemens, R.M. Garruto, L. Anderson, A. Andreadis, W.C. Wiederholt, M. Raskind and G.D. Schellenberg, Tau is a candidate gene for chromosome 17 frontotemporal dementia, Ann Neurol 43 (1998), 815-825.
172. A. Probst, J. Gotz, K.H. Wiederhold, M. Tolnay, C. Mistl, A.L. Jaton, M. Hong, T. Ishihara, V.M. Lee, J.Q. Trojanowski, R. Jakes, R.A. Crowther, M.G. Spillantini, K. Burki and M. Goedert, Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein, Acta Neuropathol (Berl) 99 (2000), 469-481.
173. M. Rapoport, H.N. Dawson, L.I. Binder, M.P. Vitek and A. Ferreira, Tau is essential to beta-amyloid-induced neurotoxicity, Proc Natl Acad Sci USA 99 (2002), 6364-6369.
174. J.J. Rebeiz, E.H. Kolodny and E.P. Richardson Jr., Corticodentatonigral degeneration with neuronal achromasia: A progressive disorder of late adult life, Trans Am Neurol Assoc 92 (1967), 23-26.
175. J.J. Rebeiz, E.H. Kolodny and E.P. Richardson Jr., Corticodentatonigral degeneration with neuronal achromasia, Arch Neurol 18 (1968), 20-33.
176. C. Rizzini, M. Goedert, J.R. Hodges, M.J. Smith, R. Jakes, R. Hills, J.H. Xuereb, R.A. Crowther and M.G. Spillantini, Tau gene mutation K257T causes a tauopathy similar to Pick's disease, J Neuropathol Exp Neurol 59 (2000), 990-1001.
177. P. Rizzu, J.C. Van Swieten, M. Joosse, M. Hasegawa, M. Stevens, A. Tibben, M.F. Niermeijer, M. Hillebrand, R. Ravid, B.A. Oostra, M. Goedert, C.M. van Duijn and P. Heutink, High prevalence of mutations in the microtubuleassociated protein tau in a population study of frontotemporal dementia in the Netherlands, Am J Hum Genet 64 (1999), 414-421.
178. T.T. Rohn, E. Head, W.H. Nesse, C.W. Cotman and D.H. Cribbs, Activation of caspase-8 in the Alzheimer's disease brain, Neurobiol Dis 8 (2001), 1006-1016.
179. T.T. Rohn, E. Head, J.H. Su, A.J. Anderson, B.A. Bahr, C.W. Cotman and D.H. Cribbs, Correlation between caspase activation and neurofibfillary tangle formation in Alzheimer's disease, Am J Pathol 158 (2001), 189-198.
180. S.M. Rosso, E. van Herpen, W. Deelen, W. Kamphorst, L.A. Severijnen, R. Willemsen, R. Ravid, M.F. Niermeijer, D. Dooijes, M.J. Smith, M. Goedert, P. Heutink and J.C. van Swieten, A novel tau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick's disease, Ann Neurol 51 (2002), 373-376.
181. K.A. Roth, Caspases, apoptosis, and Alzheimer disease: Causation, correlation, and confusion, J Neuropathol Exp Neurol 60 (2001), 829-838.
182. C. Russ, S. Lovestone, M. Baker, S.M. Pickering-Brown, P.M. Andersen, R. Furlong, D. Mann and J.F. Powell, The extended haplotype of the microtubule associated protein tau gene is not associated with Pick's disease, Neurosci Lett 299 (2001), 156-158.
183. N. Sahara, T. Tomiyama and H. Mori, Missense point mutations of tau to segregate with FTDP-17 exhibit site-specific effects on microtubule structure in COS cells: A novel action of R406W mutation, J Neurosci Res 60 (2000), 380-387.
184. Y. Sato, Y. Naito, I. Grundke-Iqbal, K. Iqbal and T. Endo, Analysis of N-glycans of pathological tau: Possible occurrence of aberrant processing of tau in Alzheimer's disease, FEBS Lett 496 (2001), 152-160.
185. A. Schneider, J. Biemat, M. von Bergen, E. Mandelkow and E.M. Mandelkow, Phosphorylation that detaches tau protein from microtubules (Ser262, Set214), also protects it against aggregation into Alzheimer paired helical filaments, Biochemistry 38 (1999), 3549-3558.
186. D.J. Selkoe, Translating cell biology into therapeutic advances in Alzheimer's disease, Nature 399 (1999), A23-31.
187. N. Sergeant, J.P. David, D. Lefranc, P. Vermersch, A. Wattez and A. Delacourte, Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases, FEBS Lett 412 (1997), 578-582.
188. N. Sergeant, A. Wattez and A. Delacourte, Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: Tau pathologies with exclusively "exon 10" isoforms, J Neurochem 72 (1999), 1243-1249.
189. S.B. Shelton and G.V.W. Johnson, Tau and HMW tau phosphorylation and compartmentalization in apoptotic neuronal PC12 cells, J Neurosci Res 66 (2001), 203-213.
190. T. Shimizu, A. Watanabe, M. Ogawara, H. Mori and T. Shirasawa, Isoaspartate formation and neurodegeneration in Alzheimer's disease, Arch Biochem Biophys 381 (2000), 225-234.
191. K. Sobue, A. Agarwal-Mawal, W. Li, W. Sun, Y. Miura and H.K. Paudel, Interaction of neuronal Cdc2-like protein kinase with microtubule-associated protein tau, J Biol Chem 275 (2000), 16673-16680.
192. E. Sontag, V. Nunbhakdi-Craig, G. Lee, G.S. Bloom and M.C. Mumby, Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A, Neuron 17 (1996), 1201-1207.
193. E. Sontag, V. Nunbhakdi-Craig, G. Lee, R. Brandt, C. Kamibayashi, J. Kuret, C.L. White III, M.C. Mumby and G.S. Bloom, Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies, J Biol Chem 274 (1999), 25490-25498.
194. A.D. Sperfeld, M.B. Collatz, H. Baier, M. Palmbach, A. Storch, J. Schwarz, K. Tatsch, S. Reske, M. Joosse, P. Heutink and A.C. Ludolph, FTDP-17: An early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation, Ann Neurol 46 (1999), 708-715.
195. M.G. Spillantini and M. Goedert, Tau protein pathology in neurodegenerative diseases, Trends Neurosci 21 (1998), 428-433.
196. M.G. Spillantini and M. Goedert, Tau gene mutations and tau pathology in frontotemporal dementia and parkinsonism linked to chromosome 17, Adv Exp Med Biol 487 (2001), 21-37.
197. M.G. Spillantini, J.R. Murrell, M. Goedert, M.R. Farlow, A. Klug and B. Ghetti, Mutation in the tau gene in familial multiple system tauopathy with presenile dementia, Proc Natl Acad Sci USA 95 (1998), 7737-7741.
198. M.G. Spillantini, H. Yoshida, C. Rizzini, P.L. Lantos, N. Khan, M.N. Rossor, M. Goedert and J. Brown, A novel tau mutation (N296N), in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies, Ann Neurol 48 (2000), 939-943.
199. K. Spittaels, C. Van den Haute, J. Van Dorpe, K. Bruynseels, K. Vandezande, I. Laenen, H. Geerts, M. Mercken, R. Sciot, A. Van Lommel, R. Loos and F. Van Leuven, Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein, Am J Pathol 155 (1999), 2153-2165.
200. K. Spittaels, C. Van den Haute, J. Van Dorpe, H. Geerts, M. Mercken, K. Bruynseels, R. Lasrado, K. Vandezande, I. Laenen, T. Boon, J. Van Lint, J. Vandenheede, D. Moechars, R. Loos and F. Van Leuven, Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice, J Biol Chem 275 (2000), 41340-41349.
201. C. Stadelmann, T.L. Deckwerth, A. Srinivasan, C. Bancher, W. Bruck, K. Jellinger and H. Lassmann, Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death, Am J Pathol 155 (1999), 1459-1466.
202. K. Stamer, R. Vogel, E. Thies, E. Mandelkow and E.M. Mandelkow, Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress, J Cell Biol 156 (2002), 1051-1063.
203. P.M. Stanford, G.M. Halliday, W.S. Brooks, J.B. Kwok, C.E. Storey, H. Creasey, J.G. Morris, M.J. Fulham and P.R. Schofield, Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: Expansion of the disease phenotype caused by tau gene mutations, Brain 123 (2000), 880-893.
204. W.H. Stoothoff and G.V. Johnson, Hyperosmotic stressinduced apoptosis and tau phosphorylation in human neuroblastoma cells, J Neurosci Res 65 (2001), 573-582.
205. W. Sun, H.Y. Qureshi, P.W. Cafferty, K. Sobue, A. AgarwalMawal, K.D. Neufield and H.K. Paudel, Glycogen synthase kinase-3beta is complexed with Tau protein in brain microtubules, J Biol Chem 277 (2002), 11933-11940.
206. M. Takahashi, Y. Tsujioka, T. Yamada, Y. Tsuboi, H. Okada, T. Yamamoto and Z. Liposits, Glycosylafion of microtubule-associated protein tau in Alzheimer's disease brain, Acta Neuropathol (Berl) 97 (1999), 635-641.
207. A. Takashima, M. Muraymna, O. Murayama, T Kohno, T. Honda, K. Yasutake, N. Nihonmatsu, M. Mercken, H. Yamaguchi, S. Sugihara and G. Wolozin, Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau, Proc Natl Acad Sci USA 95 (1998), 9637-9641.
208. A. Takeda, M.A. Smith, J. Avila, A. Nunomura, S.L. Siedlak, X. Zhu, G. Perry and L.M. Sayre, In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification, J Neurochem 75 (2000), 1234-1241.
209. Y. Takei, J. Teng, A. Harada and N. Hirokawa, Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes, J Cell Biol 150 (2000), 989-1000.
210. K. Tanemura, T. Akagi, M. Murayama, N. Kikuchi, O. Murayama, T. Hashikawa, Y. Yoshiike, J.M. Park, K. Matsuda, S. Nakao, X. Sun, S. Sato, H. Yamaguchi and A. Takashima, Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau, Neurobiol Dis 8 (2001), 1036-1045.
211. K. Tanemura, M. Murayama, T. Akagi, T Hashikawa, T. Tominaga, M. Ichikawa, H. Yamaguchi and A. Takashima, Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau, J Neurosci 22 (2002), 133-141.
212. I. Tesseur, J. Van Dorpe, K. Spittaels, C. Van den Haute, D. Moechars and F. Van Leuven, Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice, Am J Pathol 156 (2000), 951-964.
213. I. Tint, T. Slaughter, I. Fischer and M.M. Black, Acute inactivation of tau has no effect on dynamics of microtubules in growing axons of cultured sympathetic neurons, J Neurosci 18 (1998), 8660-8673.
214. B. Trinczek, J. Biernat, K. Baumann, E.M. Mandelkow and E. Mandelkow, Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules, Mol Biol Cell 6 (1995), 1887-1902.
215. J. Tucholski, J. Kuret and G.V. Johnson, Tau is modified by tissue transglutaminase in situ: Possible functional and metabolic effects of polyamination, J Neurochem 73 (1999), 1871-1880.
216. G. Tzivion and J. Avruch, 14-3-3 Proteins: Active cofactors in cellular regulation by serine/threonine phosphorylation, J Biol Chem 277 (2002), 3061-3064.
217. G. Tzivion, Y.H. Shen and J. Zhu, 14-3-3 Proteins; bringing new definitions to scaffolding, Oncogene 20 (2001), 6331-6338.
218. B. Vanhaesebroeck and D.R. Alessi, The PI3K-PDK1 connection: More than just a road to PKB, Biochem J 346 (2000), 561-576.
219. R. Vitaliani, T. Scaravilli, E. Egarter-Vigl, B. Giometto, C. Klein, F. Scaravilli, S.F. An and P.P. Pramstaller, The pathology of the spinal cord in progressive supranuclear palsy, J Neuropathol Exp Neurol 61 (2002), 268-274.
220. V. Vogelsberg-Ragaglia, J. Bruce, C. Richter-Landsberg, B. Zhang, M. Hong, J.Q. Trojanowski and V.M. Lee, Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells, Mol Biol Cell 11 (2000), 4093-4104.
221. M. von Bergen, S. Barghorn, L. Li, A. Marx, J. Biernat, E.M. Mandelkow and E. Mandelkow, Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure, J Biol Chem 276 (2001), 48165-48174.
222. M. von Bergen, P. Friedhoff, J. Biernat, J. Heberle, E.M. Mandelkow and E. Mandelkow, Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure, Proc Natl Acad Sci USA 97 (2000), 5129-5134.
223. U. Wagner, M. Utton, J.M. Gallo and C.C. Miller, Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation, J Cell Sci 109 (1996), 1537-1543.
224. A. Watanabe, K. Takio and Y. Ihara, Deamidation and isoaspartate formation in smeared tau in paired helical filaments. Unusual properties of the microtubule-binding domain of tau, J Biol Chem 274 (1999), 7368-7378.
225. C.C. Weihl, G.D. Ghadge, S.G. Kennedy, N. Hay, R.J. Miller and R.P. Roos, Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB, J Neurosci 19 (1999), 5360-5369.
226. M. Wijker, Z.K. Wszolek, E.C. Wolters, M.A. Rooimans, G. Pals, R.F. Pfeiffer, T. Lynch, R.L. Rodnitzky, K.C. Wilhelmsen and F. Arwert, Localization of the gene for rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration to chromosome 17q21, Hum Mol Genet 5 (1996), 151-154.
227. K.C. Wilhelmsen, T. Lynch, E. Pavlou, M. Higgins and T.G. Nygaard, Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22, Am J Hum Genet 55 (1994), 1159-1165.
228. R. Williamson, T. Scales, B.R. Clark, G. Gibb, C.H. Reynolds, S. Kellie, I.N. Bird, I.M. Varndell, P.W. Sheppard, I. Everall and B.H. Anderton, Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: Involvement of Src family protein kinases, J Neurosci 22 (2002), 10-20.
229. D.M. Wilson and L.I. Binder, Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease, Am J Pathol 150 (1997), 2181-2195.
230. C.M. Wischik, M. Novak, H.C. Thogersen, P.C. Edwards, M.J. Runswick, R. Jakes, J.E. Walker, C. Milstein, M. Roth and A. Klug, Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease, Proc Natl Acad Sci USA 85 (1988), 4506-4510.
231. C.W. Wittmann, M.F. Wszolek, J.M. Shulman, P.M. Salvaterra, J. Lewis, M. Hutton and M.B. Feany, Tauopathy in Drosophila: Neurodegeneration without neurofibrillary tangles, Science 293 (2001), 711-714.
232. Z.K. Wszolek, R.F. Pfeiffer, M.H. Bhatt, R.L. Schelper, M. Cordes, B.J. Snow, R.L. Rodnitzky, E.C. Wolters, F. Arwert and D.B. Calne, Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration, Ann Nettrol 32 (1992), 312-320.
233. Z.K. Wszolek, Y. Tsuboi, R.J. Uitti, L. Reed, M.L. Hutton and D.W. Dickson, Progressive supranuclear palsy as a disease phenotype caused by the S305S tau gene mutation, Brain 124 (2001), 1666-1670.
234. L. Yang and H. Ksiezak-Reding, Ubiquitin immunoreactivity of paired helical filaments differs in Alzheimer's disease and corticobasal degeneration, Acta Neuropathol (Berl) 96 (1998), 520-526.
235. P.J. Yao and P.D. Coleman, Reduction of O-linked N-acetylglucosamine-modified assembly protein-3 in Alzheimer's disease, J Neurosci 18 (1998), 2399-2411.
236. M. Yasuda, J. Takamatsu, I. D'Souza, R.A. Crowther, T. Kawamata, M. Hasegawa, H. Hasegawa, M.G. Spillantini, S. Tanimukai, P. Poorkaj, L. Varani, G. Varani, T. Iwatsubo, M. Goedert, D.G. Schellenberg and C. Tanaka, A novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto), Ann Neurol 47 (2000), 422-429.
237. S. Yen, C. Easson, P. Nacharaju, M. Hutton and S.H. Yen, FTDP-17 tau mutations decrease the susceptibility of tau to calpain I digestion, FEBS Letr 461 (1999), 91-95.
238. J. Zhang and G.V. Johnson, Tau protein is hyperphosphorylated in a site-specific manner in apoptotic neuronal PC12 cells, J Neurochem 75 (2000), 2346-2357.
239. X.Z. Zhou, O. Kops, A. Werner, P.J. Lu, M. Shen, G. Stoller, G. Kullertz, M. Stark, G. Fischer and K.P. Lu, Pinldependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins, Mol Cell 6 (2000), 873-883.